China Resources Pharmaceutical Group Limited (3320.HK)
HKD 5.0
(1.83%)
HKD 5.0
(1.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 270.39 Billion HKD | 6.41% |
| 2022 | 254.1 Billion HKD | 7.31% |
| 2021 | 236.8 Billion HKD | 18.15% |
| 2020 | 200.42 Billion HKD | -1.97% |
| 2019 | 204.45 Billion HKD | 7.78% |
| 2018 | 189.68 Billion HKD | 9.94% |
| 2017 | 172.53 Billion HKD | 10.1% |
| 2016 | 156.7 Billion HKD | 6.92% |
| 2015 | 146.56 Billion HKD | 7.97% |
| 2014 | 135.74 Billion HKD | 16.07% |
| 2013 | 116.95 Billion HKD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 139.35 Billion HKD | 0.0% |
| 2023 Q4 | 130.46 Billion HKD | 0.0% |
| 2023 FY | 270.39 Billion HKD | 6.41% |
| 2023 Q2 | 138.94 Billion HKD | 0.0% |
| 2022 Q2 | 125.71 Billion HKD | 0.0% |
| 2022 FY | 254.1 Billion HKD | 7.31% |
| 2022 Q4 | 128.38 Billion HKD | 0.0% |
| 2021 Q2 | 114.48 Billion HKD | 0.0% |
| 2021 Q4 | 122.31 Billion HKD | 0.0% |
| 2021 FY | 236.8 Billion HKD | 18.15% |
| 2020 FY | 200.42 Billion HKD | -1.97% |
| 2020 Q4 | 111.03 Billion HKD | 0.0% |
| 2020 Q2 | 89.38 Billion HKD | 0.0% |
| 2019 Q2 | 101.92 Billion HKD | 0.0% |
| 2019 FY | 204.45 Billion HKD | 7.78% |
| 2019 Q4 | 102.53 Billion HKD | 0.0% |
| 2018 FY | 189.68 Billion HKD | 9.94% |
| 2018 Q2 | 93.74 Billion HKD | 0.0% |
| 2018 Q4 | 95.94 Billion HKD | 0.0% |
| 2017 FY | 172.53 Billion HKD | 10.1% |
| 2017 Q2 | 82.73 Billion HKD | 0.0% |
| 2017 Q4 | 89.79 Billion HKD | 0.0% |
| 2016 FY | 156.7 Billion HKD | 6.92% |
| 2016 Q4 | 81.08 Billion HKD | 0.0% |
| 2016 Q2 | 75.61 Billion HKD | 0.0% |
| 2015 Q2 | 71.26 Billion HKD | 0.0% |
| 2015 FY | 146.56 Billion HKD | 7.97% |
| 2015 Q4 | 75.3 Billion HKD | 0.0% |
| 2014 Q4 | 36.64 Billion HKD | 7.97% |
| 2014 Q3 | 33.93 Billion HKD | 0.0% |
| 2014 Q2 | 33.93 Billion HKD | 0.0% |
| 2014 Q1 | 33.93 Billion HKD | 0.0% |
| 2014 FY | 135.74 Billion HKD | 16.07% |
| 2013 Q3 | 29.23 Billion HKD | 0.0% |
| 2013 FY | 116.95 Billion HKD | 0.0% |
| 2013 Q2 | 29.23 Billion HKD | 0.0% |
| 2013 Q1 | 29.23 Billion HKD | 0.0% |
| 2013 Q4 | 33.93 Billion HKD | 16.07% |
| 2012 Q4 | 29.23 Billion HKD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -104236.853% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | -2467.976% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -457440.529% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -34394.688% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -28028.559% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -25577.927% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -15744.618% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -33319.227% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -66359.708% |
| SSY Group Limited | 6.46 Billion HKD | -4083.768% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -41601.272% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -18321.97% |